General Counsel
Regeneron Pharmaceuticals, Inc. (REGN)Equibles does not estimate personal net worth.
Get an email with a short summary when Regeneron Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get REGN alertsJoseph J. LaRosa is recorded as General Counsel at Regeneron Pharmaceuticals, Inc. (REGN). The proxy statement of Regeneron Pharmaceuticals, Inc. reports total compensation of $7,458,970 for Joseph J. LaRosa in fiscal 2025, including a base salary of $916,062. Disclosed compensation is on record for 2 fiscal years. Joseph J. LaRosa has spoken on 1 investor event across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on June 12, 2026. Regeneron Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Regeneron Pharmaceuticals, Inc. includes George D. Yancopoulos, M.D., Ph.D. (Chairman), Leonard S. Schleifer, M.D., Ph.D. (Chairman), Christine A. Poon (Board Member) and 7 others.
“The meeting is being recorded and will be made available on the investor relations portion of our company website.”
Biotechnology · Healthcare
General Counsel
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, General Counsel and Secretary10 | $916,062 | $7,458,970 |
| 2021 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, General Counsel and Secretary | $810,000 | $7,126,901 |
